This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

£200 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
4 - 6 June, 2024
Excel London Platinum Suite

Michael Asensio
Director R&D at GigaGen, Inc (A subsidiary of Grifols, S.A.)


Michael Asensio is the Director of Research and Development at GigaGen, Inc. (a subsidiary of Grifols). After earning his M.S. from the UC Berkeley/UCSF joint Bioengineering program, he joined GigaGen and helped build the microfluidic and molecular biology platform technologies to produce the first recombinant polyclonal antibodies. His current role focuses on capturing and engineering antibody repertoires to create novel therapeutics for a variety of diseases.

Agenda Sessions

  • Co-Chairs' Remarks

  • Capturing, Engineering, and Recreating Diverse Human Antibody Immune Repertoires for Novel Drug Discovery